PortalPublikationenExternal beam radiation therapy improves survival in high- a...

External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients

Standard

External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. / Knipper, Sophie; Dzyuba-Negrean, Cristina; Palumbo, Carlotta; Pecoraro, Angela; Rosiello, Giuseppe; Tian, Zhe; Briganti, Alberto; Saad, Fred; Tilki, Derya; Graefen, Markus; Karakiewicz, Pierre I.

in: INT UROL NEPHROL, Jahrgang 52, Nr. 1, 01.2020, S. 59-66.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Knipper, S, Dzyuba-Negrean, C, Palumbo, C, Pecoraro, A, Rosiello, G, Tian, Z, Briganti, A, Saad, F, Tilki, D, Graefen, M & Karakiewicz, PI 2020, 'External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients', INT UROL NEPHROL, Jg. 52, Nr. 1, S. 59-66. https://doi.org/10.1007/s11255-019-02284-1

APA

Knipper, S., Dzyuba-Negrean, C., Palumbo, C., Pecoraro, A., Rosiello, G., Tian, Z., Briganti, A., Saad, F., Tilki, D., Graefen, M., & Karakiewicz, P. I. (2020). External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. INT UROL NEPHROL, 52(1), 59-66. https://doi.org/10.1007/s11255-019-02284-1

Vancouver

Knipper S, Dzyuba-Negrean C, Palumbo C, Pecoraro A, Rosiello G, Tian Z et al. External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. INT UROL NEPHROL. 2020 Jan;52(1):59-66. https://doi.org/10.1007/s11255-019-02284-1

Bibtex

@article{5fac31cb84ae43f794666285451eb8aa,
title = "External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients",
abstract = "PURPOSE: There is no contemporary proof of cancer-control benefits in octogenarian clinically localized prostate cancer (PCa) patients with life expectancy (LE) < 10 years. Therefore, cancer-specific mortality (CSM) rates after external beam radiation therapy (EBRT) vs. no local treatment (NLT) were tested in octogenarian PCa patients with LE < 10 years.METHODS: Within the surveillance, epidemiology, and end results database (2004-2015), we identified 22,361 octogenarian clinically localized PCa patients who either received EBRT or NLT. Temporal trends, cumulative incidence plots and multivariable competing-risks regression analyses (MCR) were used after propensity score matching. Sensitivity analyses were performed according to D'Amico risk groups and LE > 5 years.RESULTS: Of all, 7325 (32.8%) received EBRT vs. 15,036 (67.2%) received NLT. Rates of EBRT significantly increased over time (25.0-42.4%). Overall, 10-year CSM rates were 10.6% vs. 17.0% and 10-year other-cause mortality rates were 50.3% vs. 58.1%, in EBRT vs. NLT patients (both p < 0.001). In MCR focusing on the overall cohort, EBRT represented an independent predictor of lower CSM (hazard ratio: 0.5). In sensitivity analyses, hazard ratios of 0.5 (p < 0.001), 0.5 (p < 0.001) and 0.8 (p = 0.5) were, respectively, recorded in D'Amico high-, intermediate- and low-risk patients. In sensitivity analyses addressing patients with LE > 5 years virtually the same results were recorded.CONCLUSIONS: In octogenarian patients with LE < 10 years, EBRT seems to be associated with lower CSM in D'Amico high-risk, as well as in D'Amico intermediate-risk patients relative to their NLT counterparts. Based on these observations, greater consideration for EBRT may be given in octogenarian patients.",
author = "Sophie Knipper and Cristina Dzyuba-Negrean and Carlotta Palumbo and Angela Pecoraro and Giuseppe Rosiello and Zhe Tian and Alberto Briganti and Fred Saad and Derya Tilki and Markus Graefen and Karakiewicz, {Pierre I}",
year = "2020",
month = jan,
doi = "10.1007/s11255-019-02284-1",
language = "English",
volume = "52",
pages = "59--66",
journal = "INT UROL NEPHROL",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "1",

}

RIS

TY - JOUR

T1 - External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients

AU - Knipper, Sophie

AU - Dzyuba-Negrean, Cristina

AU - Palumbo, Carlotta

AU - Pecoraro, Angela

AU - Rosiello, Giuseppe

AU - Tian, Zhe

AU - Briganti, Alberto

AU - Saad, Fred

AU - Tilki, Derya

AU - Graefen, Markus

AU - Karakiewicz, Pierre I

PY - 2020/1

Y1 - 2020/1

N2 - PURPOSE: There is no contemporary proof of cancer-control benefits in octogenarian clinically localized prostate cancer (PCa) patients with life expectancy (LE) < 10 years. Therefore, cancer-specific mortality (CSM) rates after external beam radiation therapy (EBRT) vs. no local treatment (NLT) were tested in octogenarian PCa patients with LE < 10 years.METHODS: Within the surveillance, epidemiology, and end results database (2004-2015), we identified 22,361 octogenarian clinically localized PCa patients who either received EBRT or NLT. Temporal trends, cumulative incidence plots and multivariable competing-risks regression analyses (MCR) were used after propensity score matching. Sensitivity analyses were performed according to D'Amico risk groups and LE > 5 years.RESULTS: Of all, 7325 (32.8%) received EBRT vs. 15,036 (67.2%) received NLT. Rates of EBRT significantly increased over time (25.0-42.4%). Overall, 10-year CSM rates were 10.6% vs. 17.0% and 10-year other-cause mortality rates were 50.3% vs. 58.1%, in EBRT vs. NLT patients (both p < 0.001). In MCR focusing on the overall cohort, EBRT represented an independent predictor of lower CSM (hazard ratio: 0.5). In sensitivity analyses, hazard ratios of 0.5 (p < 0.001), 0.5 (p < 0.001) and 0.8 (p = 0.5) were, respectively, recorded in D'Amico high-, intermediate- and low-risk patients. In sensitivity analyses addressing patients with LE > 5 years virtually the same results were recorded.CONCLUSIONS: In octogenarian patients with LE < 10 years, EBRT seems to be associated with lower CSM in D'Amico high-risk, as well as in D'Amico intermediate-risk patients relative to their NLT counterparts. Based on these observations, greater consideration for EBRT may be given in octogenarian patients.

AB - PURPOSE: There is no contemporary proof of cancer-control benefits in octogenarian clinically localized prostate cancer (PCa) patients with life expectancy (LE) < 10 years. Therefore, cancer-specific mortality (CSM) rates after external beam radiation therapy (EBRT) vs. no local treatment (NLT) were tested in octogenarian PCa patients with LE < 10 years.METHODS: Within the surveillance, epidemiology, and end results database (2004-2015), we identified 22,361 octogenarian clinically localized PCa patients who either received EBRT or NLT. Temporal trends, cumulative incidence plots and multivariable competing-risks regression analyses (MCR) were used after propensity score matching. Sensitivity analyses were performed according to D'Amico risk groups and LE > 5 years.RESULTS: Of all, 7325 (32.8%) received EBRT vs. 15,036 (67.2%) received NLT. Rates of EBRT significantly increased over time (25.0-42.4%). Overall, 10-year CSM rates were 10.6% vs. 17.0% and 10-year other-cause mortality rates were 50.3% vs. 58.1%, in EBRT vs. NLT patients (both p < 0.001). In MCR focusing on the overall cohort, EBRT represented an independent predictor of lower CSM (hazard ratio: 0.5). In sensitivity analyses, hazard ratios of 0.5 (p < 0.001), 0.5 (p < 0.001) and 0.8 (p = 0.5) were, respectively, recorded in D'Amico high-, intermediate- and low-risk patients. In sensitivity analyses addressing patients with LE > 5 years virtually the same results were recorded.CONCLUSIONS: In octogenarian patients with LE < 10 years, EBRT seems to be associated with lower CSM in D'Amico high-risk, as well as in D'Amico intermediate-risk patients relative to their NLT counterparts. Based on these observations, greater consideration for EBRT may be given in octogenarian patients.

U2 - 10.1007/s11255-019-02284-1

DO - 10.1007/s11255-019-02284-1

M3 - SCORING: Journal article

C2 - 31542882

VL - 52

SP - 59

EP - 66

JO - INT UROL NEPHROL

JF - INT UROL NEPHROL

SN - 0301-1623

IS - 1

ER -